Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Colorcon
Moodys
Express Scripts
Dow

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 5,834,243

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,834,243
Title: Deformylation of f-Met peptides in bacterial expression systems
Abstract:A method for producing recombinant peptides and proteins having a diminished retention of N-formyl-methionine by coexpressing a peptide deformylase enzyme is disclosed. Also disclosed are substantially deformylated protein compositions and transformed bacterial cells and DNA vectors useful for acheiving such deformylation.
Inventor(s): Bogosian; Gregg (Ballwin, MO)
Assignee:
Application Number:08/895,939
Patent Claims:1. A method for deformylating recombinant protein produced in a bacterial host cell, which method comprises culturing a bacterial host cell expressing:

a. a first expressible DNA sequence encoding a peptide deformylase enzyme operably linked to a promoter operable in said bacterial host cell; and

b. a second expressible DNA sequence encoding a recombinant protein operably linked to a promoter operable in said bacterial host cell;

wherein said bacterial host cell has increased production of peptide deformylase enzyme in an amount effective to increase deformylation of said recombinant protein.

2. The method of claim 1 in which said recombinant protein is E. coli tryptophan synthase alpha, tryptophan synthase beta, bovine somatotropin, eel growth hormone, E. coli 1-acyl-sn-glycerol-3-phosphate acyltransferase, human granulocyte colony-stimulating factor, bovine fatty acid-binding protein, bovine cytochrome P450, methanothermus fervidus histonea, human interleukin-5, human parathyroid hormone, human gamma-interferon, E. coli threonine deaminase, or E. coli TolQ membrane protein.

3. The method of claim 2 in which said recombinant protein is human granulocyte colony stimulating factor, bovine somototropin, human gamma interferon or human interleukin-5.

4. A method for deformylating bovine somatotropin produced in a bacterial host cell, which method comprises culturing a bacterial host cell expressing:

a. a first expressible DNA sequence encoding a peptide deformylase enzyme operably linked to a promoter operable in said bacterial host cell; and

b. a second expressible DNA sequence encoding bovine somatotropin operably linked to a promoter operable in said bacterial host cell;

wherein said bacterial host cell has increased production of peptide deformylase enzyme in an amount effective to increase deformylation of said bovine somatotropin.

5. A method for production, in a transformed bacterial host cell, of a recombinant protein having a diminished retention of N-formyl methionine, which method comprises:

a. Transforming a bacterial host cell with DNA comprising:

(i) a first expressible DNA sequence encoding a peptide deformylase enzyme operably linked to a promoter operable in said bacterial host cell and

(ii) a second expressible DNA sequence encoding a recombinant protein operably linked to a promoter operable in said bacterial host cell,

b. Identifying a transformed bacterial host cell having both of said first and second expressible sequences, and

c. Culturing said transformed bacterial host cell identified in step b under conditions which cause coexpression of said recombinant protein and said peptide deformylase enzyme.

6. A method for production, in a transformed bacterial host cell, of bovine somatotropin having a diminished retention of N-formyl methionine, which method comprises:

a. Transforming a bacterial host cell with DNA comprising:

(i) a first expressible DNA sequence encoding a peptide deformylase enzyme operably linked to a promoter operable in said bacterial host cell and

(iii) a second expressible DNA sequence encoding bovine somatotropin operably linked to a promoter operable in said bacterial host cell,

b. Identifying a transformed bacterial host cell having both the first and second expressible sequences, and

c. Culturing said transformed bacterial host cell identified in step b under conditions which cause coexpression of said bovine somatotropin and said peptide deformylase enzyme.

7. The method of claim 5 in which said recombinant protein is E. coli tryptophan synthase alpha, tryptophan synthase beta, bovine somatotropin, eel growth hormone, E. coli 1-acyl-sn-glycerol-3-phosphate acyltransferase, human granulocyte colony-stimulating factor, bovine fatty acid-binding protein, bovine cytochrome P450, methanothermus fervidus histonea, human interleukin-5, human parathyroid hormone, human gamma-interferon, E. coli threonine deaminase, or E. coli TolQ membrane protein.

8. The method of claim 7 in which said recombinant protein is human granulocyte colony stimulating factor, bovine somototropin, human gamma interferon or human interleukin-5.

9. The method of claim 1, 2, 3, 4, 5, 7, or 8 in which the amino acid sequence of said peptide deformylase is substantially the same as the amino acid sequence of the peptide deformylase enzyme endogenous to said bacterial host cell.

10. The method of claim 1, 2, 3, 4, 5, 7, or 8 in which said bacterial host cell is a member of the enterobacteriaceae family.

11. The method of claim 5, 6, 7 or 8 wherein

(i) said first expressible DNA sequence is on a DNA molecule comprising at least one marker gene,

(ii) said second expressible DNA sequence is on a DNA molecule comprising at least one marker gene and

(iii) said transformed bacterial host cell is identified as having a marker trait conferred by at least one of the marker genes.

12. The method of claim 5, 6, 7 or 8 in which said first and second expressible DNA sequences are operably linked to different promoters.

13. The method of claim 12 in which at least one of said promoters is an indole acrylic acid inducible trp promoter.

14. The method of claim 12 in which said first and second expressible DNA sequences are on the same DNA molecule which molecule comprises at least one marker gene.

15. The method of claim 12 in which said first and second expressible DNA sequences are on different DNA molecules each of which comprises at least one marker gene.

16. The method of claim 5, 6, 7 or 8 in which said first and second expressible DNA sequences are operably linked to the same promoter.

17. The method of claim 16 in which said promoter is an indole acrylic acid inducible trp promoter.

18. The method of claim 5, 6, 7 or 8 in which said transformed bacterial host cell produces the protein encoded by said second expressible DNA sequence at a level which is greater than about 80% of the level produced by a bacterial host cell which, otherwise identical, does not contain said first expressible DNA sequence.

19. The method of claim 5, 7, 8, or 6 in which at least one of said expressible DNA sequences is stably integrated into the bacterial chromosome.

20. The method of claim 1, 2, 3, 4, 5, 7, or 8 in which said bacterial host cell is E. coli.

21. The method of claim 20 in which the amino acid sequence of said peptide deformylase is substantially the same as the amino acid sequence of E. coli peptide deformylase enzyme.

22. The method of claim 20 in which said bacterial host cell is of an E. coli K12 strain.

23. A method for increasing the amount of peptide deformylase produced in an E. coli host cell which method comprises:

a. Transforming an E. coli host cell with a DNA molecule comprising:

(i) a marker gene and

(ii) an expressible DNA sequence encoding an E. coli peptide deformylase enzyme operably linked to a promoter operable in E. coli,

b. Identifying a transformed E. coli host cell having a marker trait conferred by the marker gene, and

c. Culturing said transformed E. coli host cell indentified in step b under conditions which cause said transformed E. coli host cell to produce more peptide deformylase than an untransformed E. coli host cell.

24. The method of claim 23 in which said promoter is chemically inducible and said transformed E. coli host cell is cultured in the presence of an amount of inducer compound sufficient to increase peptide deformylase production to a desired level which is between the production level of an untransformed E. coli host cell and the maximal production level of said transformed E. coli host cell.

25. The method of claim 24 in which said promoter is an indole acrylic acid inducible trp promoter and said inducer compound is indole acrylic acid.

26. A transformed E. coli host cell comprising:

a) DNA sequence encoding an E. coli peptide deformylase enzyme operably linked to a promoter operable in E. coli, which transformed E. coli host cell is able to produce more peptide deformylase enzyme than an untransformed E. coli host cell, and

b) a DNA sequence encoding a recombinant protein operably linked to a promoter operable in E. coli.

27. The transformed E. coli host cell of claim 26 in which said recombinant protein is E. coli tryptophan synthase alpha, tryptophan synthase beta, bovine somatotropin, eel growth hormone, E. coli 1-acyl-sn-glycerol-3-phosphate acyltransferase, human granulocyte colony-stimulating factor, bovine fatty acid-binding protein, bovine cytochrome P450, methanothermus fervidus histonea, human interleukin-5, human parathyroid hormone, human gamma-interferon, E. coli threonine deaminase, or E. coli TolQ membrane protein.

28. The tranformed E. coli of claim 27 in which said recombinant protein is human granulocyte colony-stimulating factor, bovine somototropin, human gamma interferon or human interleukin-5.

29. A transformed E. coli host cell which comprises:

a. a first expressible DNA sequence encoding an E. coli peptide deformylase enzyme operably linked to a promoter operable in E. coli; and

b. a second expressible DNA sequence encoding bovine somatotropin operably linked to a promoter operable in E. coli;

wherein said transformed E. coli host cell is able to produce bovine somatotropin which contains less formylated methionine than that produced by a transformed E. coli host cell which, otherwise identical, is not transformed with said first DNA sequence.

30. The transformed E. coli host cell of claim 29 wherein

(i) said first expressible DNA sequence is on a DNA molecule comprising at least one marker gene,

(ii) said second expressible DNA sequence is on a DNA molecule comprising at least one marker gene and

(iii) said transformed E. coli host cell has a marker trait conferred by at least one of the marker genes.

31. The transformed E. coli host cell of claim 29 in which said peptide deformylase enzyme and said bovine somatotropin are operably linked to the same promoter.

32. A DNA composition which gives a bacterial host cell transformed with said DNA composition the ability to produce recombinant protein having a diminished retention of N-formyl methionine, which DNA composition comprises:

a. a first expressible DNA sequence encoding a peptide deformylase enzyme operably linked to a promoter operable in said bacterial host cell, and

b. a second expressible DNA sequence encoding a recombinant protein operably linked to a promoter operable in said bacterial host cell.

33. A DNA composition which gives a bacterial host cell transformed with said DNA composition the ability to produce bovine somatotropin having a diminished retention of N-formyl methionine, which DNA composition comprises:

a. a first expressible DNA sequence encoding a peptide deformylase enzyme operably linked to a promoter operable in said bacterial host cell, and

b. a second expressible DNA sequence encoding bovine somatotropin operably linked to a promoter operable in said bacterial host cell.

34. The DNA composition of claim 32 or 33 which comprises:

a. a first DNA molecule comprising a first marker gene and said first expressible DNA sequence operably linked to a first promoter, and

b. a second DNA molecule comprising a second marker gene and said second expressible DNA sequence operably linked to a second promoter.

35. The DNA composition of claim 32 or 33 which comprises a DNA molecule comprising:

a. a marker gene,

b. said first expressible DNA sequence operably linked to a first promoter, and

c. said second expressible DNA sequence operably linked to a second promoter.

36. The DNA composition of claim 23 or 33 which comprises a DNA molecule comprising:

a. a marker gene, and

b. said first and second DNA sequences operably linked to a single promoter.

Details for Patent 5,834,243

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial 2039-03-29 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial 2039-03-29 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial 2039-03-29 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial 2039-03-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Express Scripts
AstraZeneca
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.